Flax Pond Capital LLC Invests $2.62 Million in FocalTherics $FOCL

Flax Pond Capital LLC acquired a new stake in shares of FocalTherics (NASDAQ:FOCL) during the 4th quarter, Holdings Channel reports. The fund acquired 797,246 shares of the company’s stock, valued at approximately $2,623,000. FocalTherics accounts for 1.9% of Flax Pond Capital LLC’s portfolio, making the stock its 24th largest holding.

A number of other large investors also recently modified their holdings of FOCL. Financial Planning Navigators CORP bought a new position in FocalTherics in the 4th quarter worth $33,000. Kovack Advisors Inc. purchased a new stake in FocalTherics in the 4th quarter worth $53,000. Rock Springs Capital Management LP raised its holdings in FocalTherics by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after acquiring an additional 16,500 shares during the period. Finally, Leonteq Securities AG bought a new stake in FocalTherics during the fourth quarter valued at about $313,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

Insider Activity

In other FocalTherics news, Director Joshua Levine purchased 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $4.22 per share, with a total value of $42,200.00. Following the acquisition, the director owned 35,000 shares in the company, valued at approximately $147,700. The trade was a 40.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.10% of the company’s stock.

FocalTherics Price Performance

Shares of FOCL opened at $4.81 on Friday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. FocalTherics has a fifty-two week low of $1.21 and a fifty-two week high of $5.05.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). FocalTherics had a negative net margin of 41.47% and a negative return on equity of 137.61%. The business had revenue of $20.48 million for the quarter, compared to the consensus estimate of $19.46 million. Analysts expect that FocalTherics will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen downgraded FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.00.

FocalTherics Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.